The pharma giant has received the CDSCO nod to import sodium zirconium cyclosilicate powder for oral suspension (Lokelma) in ...

AstraZeneca Pharma India Ltd has received approval from India's drug regulator to import and sell sodium zirconium ...

AstraZeneca Pharma India has received approval to import and sell sodium zirconium cyclosilicate (Lokelma) for treating hyperkalemia in adults in India. The drug is indicated for the treatment of ...

AstraZeneca PLC (NASDAQ:AZN – Free Report) – Investment analysts at Zacks Research dropped their Q3 2025 earnings per share (EPS) estimates for shares of AstraZeneca in a report issued on ...

Learn more about whether AstraZeneca PLC or Intra-Cellular Therapies, Inc. is a better investment based on AAII's A+ Investor ...

NICE says that Lokelma can be used for non-dialysed patients with CKD or heart failure who have persistent hyperkalaemia with a potassium level of 6.0 mmol/litre or more that is preventing them ...

Farxiga sales were up 21% (22% at CER) to $1.94 billion, and Lokelma sales increased 35% to $150 million. Respiratory & Immunology (R&I) sales increased 27% (28% CER) to $2.13 billion. Breztri ...

Lokelma surpassed $0.5 billion in total revenue last year, and there's a growing body of evidence showing that Lokelma can help CKD and heart failure patients with hyperkalemia while maintaining ...

AZN earnings call for the period ending December 31, 2024.

Total Revenue up 21% to $54,073m, driven by a 19% increase in Product Sales, continued growth of partnered medicines (Alliance Revenue) and the achievement of sales-based milestones (Collaboration ...